ABSTRACT
Generic penetration of pharmaceuticals is almost inevitable once the patent protection on the innovator's drug has expired. Generic medicines make available a safe but cheaper option to the people and reduce burden on the healthcare system. But based on the current scenario, many biopharmaceuticals coming off patent may not have any low price generic competitors in the near future. Thus an urgent need prevails for guidelines regarding the introduction of generic biopharmaceuticals (biogenerics) in the market.